Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Bernard Munos Rides Again | Main | Read the Comments »

August 8, 2011

Gilenya's Price

Email This Entry

Posted by Derek

A couple of weeks ago, we had this discussion about the cost-effectiveness of drugs for multiple sclerosis. It was pointed out that Novartis's new Gilenya (fingolimod) is priced even higher than the drugs in the study that found that MS drugs are among the priciest in the world for their medical benefit.

Now the United Kingdom's NICE has said that Gilenya has not (so far) shown enough efficacy to justify its price. There's going to be a lot of emotionally engaged comment on both sides of this issue, but people should have been able to see this coming. And by "people", yes, I also mean Novartis.

Comments (10) + TrackBacks (0) | Category: General Scientific News | The Central Nervous System


COMMENTS

1. Anonalso on August 8, 2011 9:45 AM writes...

Novartis has to make up for the loss of Diovan somehow.

Permalink to Comment

2. PharmaHeretic on August 8, 2011 9:56 AM writes...

The most bizarre part of that pricing is that fingolimod is a small and fairly simple molecule, rather than a biological.

Permalink to Comment

3. Mr. Perceptive on August 8, 2011 10:24 AM writes...

This is no doubt, a planned pricing strategy by Novartis. Sunk costs mean nothing. As long as they can sell the stuff at a price above the marginal cost of production and sales, they make money.

Might as well start high and ratchet down as required.

When you think about it, pricing to large bulk purchasing customers will probably evolve into implicit reverse auctions. I.e., Manufacturers of products for the same indication will have margins crammed down in an iterative bidding process driven by the customers.

Or at least that's what the customers should do.

Permalink to Comment

4. anchor on August 8, 2011 10:32 AM writes...


#2 - right on the money, I say! Novartis, greed for the lack of better word is not good. The UK decision will put some sense on Novartis.

Permalink to Comment

5. Quintus on August 8, 2011 11:30 AM writes...

Novartis need the money to finance the #%%*¥ stupid campus

Permalink to Comment

6. Bbooooooya on August 8, 2011 11:07 PM writes...

It may well be true that the first gilenyia pill cost x hundred million, and each subsequent only costs a few dimes. If big pharma based it's margins o the dimes, no drugs would ever get discovered again. Maybe we can live without a new ED drug, or a drug to replace the exercise we're too lazy to take, but big pharma also makes some drugs that help people.

Permalink to Comment

7. simpl on August 9, 2011 10:35 AM writes...

Here is an article, presumably by an MS specialist, who is confused about risks, benefits and cost:
http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(11)70110-7/fulltext
The same issue also compares Gilenia with interferon, which was NICEs concern.
It is possible that the QALY methodology was something that made the higher price look appropriate.
Also relevant might be the short patent life of the molecule(2014?). I assume that the MS indication is also protected, and that other PharmaCos are looking for molecules with S1P activity.

Permalink to Comment

8. Observer on August 10, 2011 11:04 AM writes...

Among MS therapies, keep in mind that interferons Avonex, Betaferon, and Rebif as well as Copaxone never got NICE approval either. I believe only Tysabri did so.

As I understand it, the ABCRs are available in the UK to those with private insurance or can pay out of pocket.

Permalink to Comment

9. Daniel on August 11, 2011 10:56 AM writes...

Does anyone think that this setback will have any substantial impact on the near future sales figures or bottom line earnings of Novartis?

Permalink to Comment

10. Christine on December 4, 2011 2:27 PM writes...

I don't know what happened since this story was written, but I went to one of many regular MS dinner discussions offered to patients in November 2011, and the Gilenya sales rep told me that if I switch to Gilenya and have standard health insurance, it will be No_Copay. I pay $50 every three months to inject myself with Rebif...

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern